Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors
- 29 January 1994
- journal article
- clinical trial
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 15, s187-s193
- https://doi.org/10.1016/0098-2997(94)90028-0
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteersInternational Journal of Clinical and Laboratory Research, 1993
- Heart failure is a dominant deficiency of coenzyme Q10 and challenges for future clinical research on CoQ10Journal of Molecular Medicine, 1993
- Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled StudyThe Journal of Clinical Pharmacology, 1993
- Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Role of oxidized low density lipoprotein in atherogenesis.Journal of Clinical Investigation, 1991
- Might treatment of hypercholesterolaemia increase non-cardiac mortality?The Lancet, 1991
- PLASMA MEVALONATE RESPONSE IN LOVASTATIN-RELATED MYOPATHYThe Lancet, 1989
- LOVASTATIN, ISOPRENES, AND MYOPATHYThe Lancet, 1989
- Studies on reduced and oxidized coenzyme Q (ubiquinones). II. The determination of oxidation-reduction levels of coenzyme Q in mitochondria, microsomes and plasma by high-performance liquid chromatographyBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1982